Evidence map›Paper›PMID 38084874›Full record

ArticleThe Journal of antimicrobial chemotherapy2024

Antimicrobial use and combination of resistance phenotypes in bacteraemic Escherichia coli in primary care: a study based on Japanese national data in 2018.

Yumiko Hosaka, Yuichi Muraki, Toshiki Kajihara, Sayoko Kawakami, Aki Hirabayashi, Masahiro Shimojima, Hiroki Ohge, Motoyuki Sugai, Koji Yahara

Open access · hybridAbstract read
In one paragraph

Article in The Journal of antimicrobial chemotherapy, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
0.2field-weighted citation impact, top 40% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 1 citations in OpenAlex.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 4 institutions in 1 country.

Yumiko HosakaAntimicrobial Resistance Research Center, National Institute of Infectious Diseases, Tokyo, Japan.
Yuichi MurakiDepartment of Clinical Pharmacoepidemiology, Kyoto Pharmaceutical University, Kyoto, Japan.ORCID 0000-0001-6951-5676
Toshiki KajiharaAntimicrobial Resistance Research Center, National Institute of Infectious Diseases, Tokyo, Japan.ORCID 0000-0002-7576-2654
Sayoko KawakamiAntimicrobial Resistance Research Center, National Institute of Infectious Diseases, Tokyo, Japan.
Aki HirabayashiAntimicrobial Resistance Research Center, National Institute of Infectious Diseases, Tokyo, Japan.
Masahiro ShimojimaDepartment of Academics, SUGIYAMA-GEN Co., Ltd, Tokyo, Japan.
Hiroki OhgeDepartment of Infectious Diseases, Hiroshima University Hospital, Hiroshima, Japan.
Motoyuki SugaiAntimicrobial Resistance Research Center, National Institute of Infectious Diseases, Tokyo, Japan.
Koji YaharaAntimicrobial Resistance Research Center, National Institute of Infectious Diseases, Tokyo, Japan.ORCID 0000-0003-4289-1115
National Institute of Infectious Diseases · JPHiroshima University Hospital · JPKyoto Pharmaceutical University · JPSugiyama Jogakuen University · JP

Funding

Ministry of Health, Labour and Welfare, Japan JPMH22HA1002
6 · The paper itself

Abstract

backgroundAntimicrobial use (AMU) in primary care is a contributing factor to the emergence of antimicrobial-resistant bacteria. We assessed the potential effects of AMU on the prevalence of a combination of resistance phenotypes in bacteraemic Escherichia coli in outpatient care settings between primary care facilities ('clinics') and hospitals.

methodsPopulation-weighted total AMU calculated from the national database was expressed as DDDs per 1000 inhabitants per day (DID). National data for all routine microbiological test results were exported from the databases of a major commercial clinical laboratory, including 16 484 clinics, and the Japan Nosocomial Infections Surveillance, including 1947 hospitals. AMU and the prevalence of combinations of resistance phenotypes in bacteraemic E. coli isolates were compared between clinics and hospitals.

resultsThe five most common bacteria isolated from patients with bacteraemia were the same in clinics, outpatient settings and inpatient settings in hospitals, with E. coli as the most frequent. Oral third-generation cephalosporins and fluoroquinolones were the top two AMU outpatient drugs, except for macrolides, and resulted in at least three times higher AMU in clinics than in hospitals. The percentage of E. coli isolates resistant to both drugs in clinics (18.7%) was 5.6% higher than that in hospitals (13.1%) (P < 10-8).

conclusionsSignificant AMU, specifically of oral third-generation cephalosporins and fluoroquinolones, in clinics is associated with a higher prevalence of E. coli isolates resistant to both drugs. This study provides a basis for national interventions to reduce inappropriate AMU in primary care settings.

Indexed as

Anti-Infective AgentsBacteremiaAnti-Bacterial AgentsCephalosporinsDrug Resistance, BacterialEscherichia coliFluoroquinolonesHumansJapanPrimary Health CareAnti-Bacterial AgentsAnti-Infective AgentsCephalosporinsFluoroquinolones

Identifiers

PMID38084874
PMCPMC10832589
OpenAlexW4389627639

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.